King Luther Capital Management Corp Raises Position in PRA Health Sciences, Inc. (PRAH)

King Luther Capital Management Corp increased its holdings in PRA Health Sciences, Inc. (NASDAQ:PRAH) by 5.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 122,497 shares of the medical research company’s stock after buying an additional 6,730 shares during the quarter. King Luther Capital Management Corp owned about 0.19% of PRA Health Sciences worth $9,331,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the stock. Renaissance Group LLC boosted its position in PRA Health Sciences by 2.5% in the 2nd quarter. Renaissance Group LLC now owns 5,239 shares of the medical research company’s stock worth $393,000 after purchasing an additional 126 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its position in PRA Health Sciences by 1.9% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,505 shares of the medical research company’s stock worth $638,000 after purchasing an additional 160 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in PRA Health Sciences by 12.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after purchasing an additional 160 shares in the last quarter. Smith Asset Management Group LP boosted its position in PRA Health Sciences by 0.5% in the 2nd quarter. Smith Asset Management Group LP now owns 61,115 shares of the medical research company’s stock worth $4,584,000 after purchasing an additional 320 shares in the last quarter. Finally, Forward Management LLC boosted its position in PRA Health Sciences by 10.1% in the 2nd quarter. Forward Management LLC now owns 5,242 shares of the medical research company’s stock worth $394,000 after purchasing an additional 480 shares in the last quarter. Institutional investors own 98.49% of the company’s stock.

PRA Health Sciences, Inc. (NASDAQ:PRAH) opened at $81.00 on Wednesday. PRA Health Sciences, Inc. has a 52-week low of $52.76 and a 52-week high of $84.38. The stock has a market capitalization of $5,186.81, a P/E ratio of 30.09, a PEG ratio of 1.42 and a beta of 0.40. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.01 and a current ratio of 1.01.

PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.03. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. The firm had revenue of $494.55 million for the quarter, compared to analyst estimates of $477.89 million. During the same quarter last year, the firm posted $0.64 EPS. The business’s revenue was up 23.7% on a year-over-year basis. analysts expect that PRA Health Sciences, Inc. will post 3.2 earnings per share for the current fiscal year.

Several equities research analysts have commented on PRAH shares. Robert W. Baird upped their price objective on PRA Health Sciences from $82.00 to $83.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 8th. Credit Suisse Group increased their target price on PRA Health Sciences from $80.00 to $84.00 and gave the company an “outperform” rating in a research report on Tuesday, August 8th. SunTrust Banks reiterated a “buy” rating on shares of PRA Health Sciences in a research report on Wednesday, August 9th. Citigroup reiterated a “buy” rating and set a $93.00 target price (up previously from $90.00) on shares of PRA Health Sciences in a research report on Thursday, August 10th. Finally, Jefferies Group reiterated a “buy” rating and set a $92.00 target price (up previously from $88.00) on shares of PRA Health Sciences in a research report on Thursday, August 10th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $89.09.

In other news, Director Matthew P. Young sold 5,115 shares of the stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $79.90, for a total transaction of $408,688.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 2.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/12/06/king-luther-capital-management-corp-raises-position-in-pra-health-sciences-inc-prah.html.

PRA Health Sciences Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply